
-
SCYNEXIS NasdaqGM:SCYX SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Location: 1 Evertrust Plaza, Jersey City, NJ, 07302-6548, United States | Website: https://www.scynexis.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-4.875M
Cash
59.3M
Avg Qtr Burn
-6.002M
Short % of Float
1.84%
Insider Ownership
1.89%
Institutional Own.
30.03%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Brexafemme (Ibrexafungerp) Details Vulvovaginal Candidiasis, Yeast Infection | Approved Quarterly sales | |
Brexafemme (Ibrexafungerp) Details Fungal infections | Approved Quarterly sales | |
SCY-078 Details Invasive Candidiasis | Phase 3 Data readout | |
SCY-247 Details Fungal infections | Phase 1 Data readout |